CAPR
Capricor Therapeutics, Inc.
There isn't enough reported data to score CAPR yet.
CAPR Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
CAPR's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
CAPR PE Valuation
CAPR has no meaningful PE right now: it lost money over the past year.
CAPR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect CAPR's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
CAPR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.64 | -$0.89 |
| Q2 2026 | -$2.45 | -$0.86 |
| Q1 2026 | -$2.32 | -$0.95 |
| Q4 2025 | -$2.26 | -$1.11 |
| Q3 2025 | -$1.75 | -$0.68 |
| Q2 2025 | -$1.59 | -$0.65 |
| Q1 2025 | -$1.37 | -$0.49 |
| Q4 2024 | -$1.15 | -$0.27 |
CAPR lost $2.64 per share over the past year, a bigger loss than the year before.
CAPR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $11.1M | -7.9% |
| Q3 2024 | $2.3M | -63% |
| Q2 2024 | $4M | +1.4% |
| Q1 2024 | $4.9M | +64% |
| Q4 2023 | $12.1M | +1159% |
| Q3 2023 | $6.2M | +289% |
| Q2 2021 | $204.1K | +309% |
| Q1 2021 | $40.8K | -78% |
CAPR's revenue is shrinking: $11M last quarter, down 7.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2024 | -69% | -59 points |
| Q3 2024 | -575% | -464 points |
| Q2 2024 | -292% | -94 points |
| Q1 2024 | -209% | +65 points |
| Q4 2023 | -11% | +830 points |
| Q3 2023 | -111% | +296 points |
| Q2 2023 | -198% | N/A |
| Q1 2023 | -274% | N/A |
CAPR's operating margin was −69% last quarter, down 59 points from the same quarter a year ago.
CAPR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$37.5M | -$17.8M |
| Q2 2026 | -$35.5M | -$15.1M |
| Q1 2026 | -$34.4M | -$27M |
| Q4 2025 | -$25.2M | -$9.9M |
| Q3 2025 | -$19.7M | -$8.1M |
| Q2 2025 | -$20.4M | -$8.1M |
| Q1 2025 | -$7.3M | -$5.5M |
| Q4 2024 | -$15.3M | -$3.1M |
CAPR has burned cash in almost every quarter: −$133M over the past year, against −$63M the year before.
CAPR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +202K shares |
| 1 year | +27% | +12.4M shares |
| 3 years | +129% | +32.8M shares |
| 5 years | +154% | +35.3M shares |
| Available history | +745% | +51.2M shares |
CAPR has 58M diluted shares, up 27% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
CAPR Net Leverage
CAPR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CAPR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.7 | Neutral |
| Stochastic | 67.4 | Neutral |
CAPR's weekly RSI is 44 (neutral) and its Stochastic is 67 (neutral).
CAPR PE vs Healthcare Sector
CAPR has no meaningful PE right now: it lost money over the past year.
CAPR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.92 | 29% above |
| 20 week MA | $10.2 | 0.1% above |
| 50 week MA | $20.9 | 51% below |
| 100 week MA | $15.5 | 34% below |
| 200 week MA | $10.8 | 5.4% below |
CAPR has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 5.4% below its 200-week average.
CAPR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.16 | $3.90 | +236% |
| 2021 | $3.90 | $3.39 | -13% |
| 2022 | $3.39 | $3.52 | +3.8% |
| 2023 | $3.52 | $4.89 | +39% |
| 2024 | $4.89 | $14.1 | +188% |
| 2025 | $14.1 | $29.7 | +111% |
| 2026 YTD | $29.7 | $10.2 | -66% |
CAPR is down 66% so far in 2026, after finishing higher in five of the previous six years.